ERBB2 and glioblastoma: Furthermore, results from a recently published phase 1 clinical study regarding local application of HER2-specific CAR-NK92 cells for the treatment of recurrent glioblastoma, the primary objective of which was to evaluate the safety and tolerability 24 weeks post-injection, revealed that a dose of 1 × 108 irradiated CAR-NK92 cells did not cause any side effects [330].